Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/212720
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy

AutorFerrero, V. T.; Oset, M. M.; Masferrer, J. P.; Pardo, E. H.; Sorolla, E. J.; Largo, S. C.
Palabras clavePelvic 3D radiotherapy
Proctalgia
Breakthrough pain
Fecha de publicación2019
EditorSpringer Nature
CitaciónClinical and Translational Oncology 21: 1707–1711 (2019)
Resumen[Purpose] Radiotherapy-induced dysfunction of the gastrointestinal tract is common in cancer patients and has a significant impact on their quality of life. In this study, we investigated the prevalence of breakthrough cancer pain (BTcP) in patients undergoing 3D pelvic radiotherapy and who had proctalgia. [Methods] This observational, multicenter, cross-sectional epidemiological study was performed in 13 Spanish hospitals. Data were obtained on the presence and characteristics of BTcP, demographics, common comorbidities, and treatments prescribed to the patients. [Results] The prevalence of BTcP in patients undergoing pelvic 3D external radiotherapy with proctalgia (N = 105) was 48.6% (95% CI 39.0–58.1%). BTcP was further characterized in 59 patients. The mean (± SD) intensity of the BTcP episodes was 7.45 ± 1.47 in a visual analog scale. We found several statistically significant associations between the descriptive variables of BTcP with demographic and clinical variables associated with the tumor or the patient, such as an increased number of BTcP episodes per day depending on the presence or absence of diabetes (p = 0.001, Chi-square) or time to the onset of pain relief depending on the location of the tumor (p = 0.019, Chi-square). Fentanyl was the drug of choice in BTcP episodes for 95% of the patients. [Conclusions] This study demonstrated a high prevalence of BTcP prevalence in cancer patients undergoing pelvic 3D radiotherapy and with proctalgia. Although the variables determining the onset of BTcP are still unclear, our results could help in the design of future clinical studies addressing the treatment of BTcP in these patients.
DescripciónThe PrevaDIOR Study Group: Tormo, Vicente; Marcos, Marta; Pardo, José; Aymar, Neus; Hortelano, Eduardo; Flaquer, Amanda; Jorda, Esther; Cordoba, Sofia; Corona, Juan Antonio; Ferrer, Carlos; Frances, Alicia; Morillo, Virginia; Bouche, Ana; Marin, Susana; Cambray, María; Ventura, Montse; Pérez, Héctor; Hernández, Ruth; Martín, José Javier; Lorenzo, Leonardo; Fuentes, Claudio; Zurita, Mercedes; Moral, Rosario del; Muñoz, Victor; González, Alba; Enguix, Manuel; Martínez, Marta; Ortiz, María José; Fernández, M. Carmen; Cardenas, Enrique; Lozano, Antonio José
Versión del editorhttps://doi.org/10.1007/s12094-019-02102-1
URIhttp://hdl.handle.net/10261/212720
DOI10.1007/s12094-019-02102-1
Identificadoresdoi: 10.1007/s12094-019-02102-1
issn: 1699-048X
issn: 1699-3055
Aparece en las colecciones: (IBIS) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

4
checked on 20-mar-2024

WEB OF SCIENCETM
Citations

5
checked on 21-feb-2024

Page view(s)

91
checked on 28-mar-2024

Download(s)

26
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.